This method could further be modified and applied to study the metabolism of non-APP BACE1 substrates, that have been implicated in chronic adverse events, such as cognitive decline, reported in Phase III BACE1 inhibitor clinical trials24–26. Here, BACE1 is linked to Mental deterioration.